SCNI Regains Nasdaq Compliance As Traders Reassess Risk

Scinai Immunotherapeutics Ltd. stocks have been trading up by 41.38 percent amid heightened optimism over its latest biotech developments.

Live Update At 08:32:46 EDT: On Tuesday, October 13, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 41.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SCNI has been trading like a classic small-cap biotech trying to rebuild trust. Recent daily closes slid from around $1.86–$1.98 to the $1.16–$1.22 zone, showing clear profit-taking and fading momentum after earlier strength. That pullback matters because SCNI only recently clawed back over the $1.00 level long enough to regain Nasdaq compliance, removing the delisting overhang.

Intraday, the 5‑minute chart shows a wild spike from roughly $1.13 to a high near $3.34 early in the session, then a sharp fade into the high $1s and mid $1s. For traders, that screams dilution fears, profit-taking, and algo-driven volatility more than steady accumulation.

On the fundamentals, Scinai Immunotherapeutics posted about $1.31M in revenue and trades at roughly 1.22x sales, with an enterprise value near $7.83M. The price‑to‑book near 0.64 tells you the market values SCNI at a discount to its net assets. Returns on equity and assets are deeply negative, typical for a clinical‑stage player burning cash to fund science. That mix — low valuation, real assets, heavy losses — sets up SCNI as a pure trading vehicle around news and sentiment rather than steady earnings.

Why Traders Are Watching SCNI Now

SCNI is back on the Nasdaq right side of the tracks after regaining compliance with the $1.00 minimum bid price rule. For traders, that single change removes the biggest binary risk: an outright delisting that could have crushed liquidity and forced many funds and brokers to step away. With Nasdaq confirming that the bid‑price deficiency matter is closed, the immediate governance cloud over Scinai Immunotherapeutics is gone.

The path back to compliance was simple but important. SCNI needed its share price to trade at or above $1.00 for a set period. It delivered 19 consecutive trading days above that mark. That tells you there was enough demand — or at least tight enough supply — to sustain the level, not just a one‑day pop and drop.

Now the narrative can shift. Instead of asking, “Will SCNI stay listed?” traders can focus on what might actually move the stock next: progress in the NanoAb immunology programs and traction in the CDMO business. NanoAb work is the high‑beta science story; any meaningful update there can light up the tape. The CDMO push is slower but steadier — if Scinai Immunotherapeutics lands more contracts, that can add recurring revenue and help smooth the burn.

Combine that with a chart showing both big intraday ranges and a recent pullback, and SCNI becomes a textbook ticker for active trading strategies — breakout plays on news, dip buys into key levels, and tight risk management around support and resistance.

Conclusion

For active traders, SCNI now trades in a cleaner lane. The Nasdaq minimum bid price issue is resolved, the delisting threat has been taken off the table, and the compliance matter is formally closed. That alone can draw back some liquidity that stepped aside while Scinai Immunotherapeutics sat under the delisting cloud.

The fundamentals remain what they are: modest revenue, negative returns, and a valuation that prices SCNI below book value. This is not a value stock story; it is a catalyst and sentiment story. NanoAb pipeline headlines and CDMO execution will likely dictate the next big legs up or down. The recent intraday spike from nearly $1 to above $3, followed by a sharp fade, is a warning and an opportunity — SCNI rewards disciplined trading and punishes greed.

Traders studying Scinai Immunotherapeutics should map key price levels, watch volume like a hawk, and treat every news update as a potential volatility spark, not a guarantee of follow‑through. As Tim Sykes likes to say, “Volatility is your best friend and your worst enemy — it all depends on how prepared you are.” As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” SCNI now sits in that sweet spot where the structural risk has eased, but the price action still demands respect — perfect terrain for educated, rules‑based trading, and nothing more.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks